CN117427027B - 一种祛痘组合物及其制备方法 - Google Patents
一种祛痘组合物及其制备方法 Download PDFInfo
- Publication number
- CN117427027B CN117427027B CN202311765339.6A CN202311765339A CN117427027B CN 117427027 B CN117427027 B CN 117427027B CN 202311765339 A CN202311765339 A CN 202311765339A CN 117427027 B CN117427027 B CN 117427027B
- Authority
- CN
- China
- Prior art keywords
- acne
- removing composition
- fermentation product
- allantoin
- panthenol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 51
- 206010000496 acne Diseases 0.000 title claims abstract description 51
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title abstract description 12
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 86
- 241000186660 Lactobacillus Species 0.000 claims abstract description 45
- 238000000855 fermentation Methods 0.000 claims abstract description 45
- 230000004151 fermentation Effects 0.000 claims abstract description 45
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 45
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 43
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims abstract description 43
- 229960000458 allantoin Drugs 0.000 claims abstract description 43
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims abstract description 43
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims abstract description 42
- 229940101267 panthenol Drugs 0.000 claims abstract description 42
- 239000011619 pantothenol Substances 0.000 claims abstract description 42
- 235000020957 pantothenol Nutrition 0.000 claims abstract description 42
- 235000018782 Dacrydium cupressinum Nutrition 0.000 claims abstract description 27
- 235000013697 Pinus resinosa Nutrition 0.000 claims abstract description 27
- 239000003906 humectant Substances 0.000 claims abstract description 25
- 239000002904 solvent Substances 0.000 claims abstract description 22
- 239000000945 filler Substances 0.000 claims abstract description 18
- 239000000463 material Substances 0.000 claims abstract description 18
- 239000003755 preservative agent Substances 0.000 claims abstract description 16
- 230000002335 preservative effect Effects 0.000 claims abstract description 16
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims abstract description 3
- 239000000047 product Substances 0.000 claims description 45
- 125000001453 quaternary ammonium group Chemical class 0.000 claims description 37
- 240000005020 Acaciella glauca Species 0.000 claims description 26
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 18
- 240000007263 Pinus koraiensis Species 0.000 claims description 18
- 235000011615 Pinus koraiensis Nutrition 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 17
- 238000003756 stirring Methods 0.000 claims description 13
- 238000001914 filtration Methods 0.000 claims description 10
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 claims description 10
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 9
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims description 9
- 239000004475 Arginine Substances 0.000 claims description 9
- 229930186217 Glycolipid Natural products 0.000 claims description 9
- 235000007303 Thymus vulgaris Nutrition 0.000 claims description 9
- 230000003255 anti-acne Effects 0.000 claims description 9
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 9
- 239000004359 castor oil Substances 0.000 claims description 9
- 235000019438 castor oil Nutrition 0.000 claims description 9
- 235000011187 glycerol Nutrition 0.000 claims description 9
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 9
- 229960005323 phenoxyethanol Drugs 0.000 claims description 9
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 9
- 239000004299 sodium benzoate Substances 0.000 claims description 9
- 235000010234 sodium benzoate Nutrition 0.000 claims description 9
- 239000001585 thymus vulgaris Substances 0.000 claims description 9
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 8
- 229940087068 glyceryl caprylate Drugs 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000002562 thickening agent Substances 0.000 claims description 8
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 230000002421 anti-septic effect Effects 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical group O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims description 5
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 5
- -1 hydroxypropyl cyclodextrin Chemical compound 0.000 claims description 5
- 229960002510 mandelic acid Drugs 0.000 claims description 5
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 2
- 241000186612 Lactobacillus sakei Species 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims 1
- 229940035437 1,3-propanediol Drugs 0.000 claims 1
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 claims 1
- 240000002657 Thymus vulgaris Species 0.000 claims 1
- 229940100524 ethylhexylglycerin Drugs 0.000 claims 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims 1
- 229960003885 sodium benzoate Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 241000186427 Cutibacterium acnes Species 0.000 abstract description 9
- 229940055019 propionibacterium acne Drugs 0.000 abstract description 9
- 230000003020 moisturizing effect Effects 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 241000534656 Pinus resinosa Species 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 34
- 230000000052 comparative effect Effects 0.000 description 23
- 210000003491 skin Anatomy 0.000 description 22
- 108010003272 Hyaluronate lyase Proteins 0.000 description 10
- 102000001974 Hyaluronidases Human genes 0.000 description 10
- 230000000844 anti-bacterial effect Effects 0.000 description 10
- 229960002773 hyaluronidase Drugs 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 description 8
- 241000246358 Thymus Species 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 6
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (1R)-1,3-butanediol Natural products CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 5
- 229920002385 Sodium hyaluronate Polymers 0.000 description 5
- 229940010747 sodium hyaluronate Drugs 0.000 description 5
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 102000002689 Toll-like receptor Human genes 0.000 description 4
- 108020000411 Toll-like receptor Proteins 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000001376 precipitating effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 208000020154 Acnes Diseases 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000037313 granulation tissue formation Effects 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9755—Gymnosperms [Coniferophyta]
- A61K8/9767—Pinaceae [Pine family], e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种祛痘组合物及其制备方法,祛痘组合物按质量分数包括以下组分:保湿剂7‑20%、季铵盐‑73 0.002‑0.05%、赤松叶提取物0.01‑0.02%、乳酸杆菌发酵产物0.0045‑0.01%、皮肤调理剂0.2‑5%、尿囊素0.15‑0.3%、泛醇0.2‑1%、甘草酸二钾0.05‑0.2%、防腐剂0.6‑1%、增溶剂0.3‑0.8%、辅料0.1‑3%,以上组分的质量分数相加不超过100%,余量为填料。本发明对抑制痤疮丙酸杆菌有良好的效果,在保证祛痘效果的同时也具有保湿、舒缓等多重功效。
Description
技术领域
本发明涉及化妆品领域,特别涉及一种祛痘组合物及其制备方法。
背景技术
痤疮又称“痘痘”,是最为普遍的皮肤疾病。其发病机理主要有以下几点:内分泌失调,雄性激素分泌过多导致油脂分泌旺盛;毛囊皮脂腺导管角化异常;痤疮丙酸杆菌、金黄色葡萄球菌以及表皮葡萄球菌是造成痤疮发病的相关微生物,2种葡萄球菌会造成伤口化脓性感染,使得痘痘红肿、脓包;其中痤疮丙酸杆菌条件致病菌驱动着炎症反应;过度免疫反应等等也是其重要的组成部分,痘痘要是长期不处理或采取简单粗暴的挤压会引起红肿、感染,严重甚至会溃烂,导致患者留下疤痕,甚至会影响其心理成长。
现有的祛痘产品原料种类繁多功效较为单一,抑制痤疮丙酸杆菌的效果不强。
发明内容
针对现有祛痘组合物的问题,本发明提出一种祛痘组合物及制备方法,该祛痘组合物对抑制痤疮丙酸杆菌有良好的效果,在保证祛痘效果的同时也具有保湿、舒缓等多重功效。
一种祛痘组合物,按质量分数包括以下组分:保湿剂7-20%、季铵盐-73 0.002-0.05%、赤松叶提取物0.01-0.02%、乳酸杆菌发酵产物0.0045-0.01%、皮肤调理剂0.2-5%、尿囊素0.15-0.3%、泛醇0.2-1%、甘草酸二钾0.05-0.2%、防腐剂0.6-1%、增溶剂0.3-0.8%、辅料0.1-3%,以上组分的质量分数相加不超过100%,余量为填料;
其中,所述皮肤调理剂为烟酰胺、扁桃酸、精氨酸、糖脂、甘油辛酸酯、黄檗树皮提取物、欧百里香提取物中的任意一种或多种的组合。
根据本发明提出的祛痘组合物,利用季铵盐-73、赤松叶提取物、乳酸杆菌发酵产物、尿囊素、甘草酸二钾与泛醇等为主要祛痘组合物,通过季铵盐-73可以有效抑制痤疮丙酸杆菌的活性,维护微生态平衡,赤松叶提取物、乳酸杆菌发酵产物能抑制Toll样受体激活,减少炎症因子,同时配合尿囊素、甘草酸二钾与泛醇能促进细胞组织的生长,能影响表皮的快速粒状化过程,加快皮肤更新,减轻创面炎症反应、促进肉芽组织形成、纤维细胞的快速增殖、从而加速组织创面愈合的过程,具备保湿、舒缓和祛痘等多重功效。
另外,根据本发明提供的祛痘组合物,还可以具有如下附加的技术特征:
较佳的,所述保湿剂为甘油、1、3-丙二醇、丁二醇中的任意一种或多种的组合。
较佳的,所述防腐剂为苯氧乙醇、苯甲酸钠、乙基己基甘油中的一种或多种的组合。
较佳的,所述增溶剂为PEG-40 氢化蓖麻油。
较佳的,所述辅料为EDTA二钠、羟基乙酸、增稠剂中的任一种或多种的组合。
较佳的,所述增稠剂为卡波姆、丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物、黄原胶中的任一种或多种的组合。
较佳的,所述填料为水。
本发明还提出一种祛痘组合物的制备方法,包括以下步骤:
(1)将尿囊素、保湿剂加入至填料中,加热至第一预设温度,直至保湿剂搅拌溶解;
(2)待温度冷却至第二预设温度以下时,加入季铵盐-73并搅拌均匀;
(3)依次加入皮肤调理剂、赤松叶提取物、乳酸杆菌发酵产物、泛醇、甘草酸二钾、防腐剂、增溶剂、辅料,搅拌均匀后即可过滤出料。
另外,根据本发明提供的祛痘组合物的制备方法,还可以具有如下附加的技术特征:
较佳的,第一预设温度为65-75℃,第二预设温度为60℃。
本发明的有益效果至少包括:
(1)通过季铵盐-73可以有效抑制痤疮丙酸杆菌的活性,维护微生态平衡;
(2)通过赤松叶提取物、乳酸杆菌发酵产物能抑制Toll样受体激活,减少炎症因子;
(3)配合尿囊素、甘草酸二钾与泛醇能促进细胞组织的生长,能影响表皮的快速粒状化过程,加快皮肤更新,减轻创面炎症反应、促进肉芽组织形成、纤维细胞的快速增殖、从而加速组织创面愈合的过程。
本发明的附加方面和优点将在下面的描述中部分给出,部分将从下面的描述中变得明显,或通过本发明的实践了解到。
具体实施方式
为使本发明的目的、特征和优点能够更加明显易懂,下面结合实施例对本发明的具体实施方式做详细的说明。实施例中给出了本发明的若干实施例。但是,本发明可以以许多不同的形式来实现,并不限于本文所描述的实施例。相反地,提供这些实施例的目的是使对本发明的公开内容更加透彻全面。
实施例1
一种祛痘组合物,按质量分数包括以下组分:保湿剂10%、季铵盐-73 0.02%、赤松叶提取物0.015%、乳酸杆菌发酵产物0.0075%、皮肤调理剂4%、尿囊素0.2%、泛醇0.4%、甘草酸二钾0.12%、防腐剂0.8%、增溶剂0.6%、辅料0.7%,余量为填料。
其中,所述保湿剂为甘油、1、3-丙二醇、丁二醇,所述皮肤调理剂为扁桃酸、精氨酸、糖脂、甘油辛酸酯、黄檗树皮提取物、欧百里香提取物,所述防腐剂为苯氧乙醇、苯甲酸钠、乙基己基甘油,所述增溶剂为PEG-40 氢化蓖麻油,所述辅料为EDTA二钠、羟基乙酸,所述填料为水;
需要说明的是,赤松叶提取物、乳酸杆菌发酵产物可通过以下方法制备得到:提取赤松叶水,将赤松叶水与沙克乳酸杆菌混合并在37℃的条件下发酵48h,之后经过灭菌、过滤、浓缩、添加丁二醇、羟丙基环糊精和双丙甘醇、过滤得到最终产物即为赤松叶提取物、乳酸杆菌发酵产物。
利用季铵盐-73、赤松叶提取物、乳酸杆菌发酵产物、尿囊素、甘草酸二钾与泛醇等为主要祛痘组合物,通过季铵盐-73可以有效抑制痤疮丙酸杆菌的活性,维护微生态平衡,赤松叶提取物、乳酸杆菌发酵产物能抑制Toll样受体激活,减少炎症因子,同时配合尿囊素、甘草酸二钾与泛醇能促进细胞组织的生长,能影响表皮的快速粒状化过程,加快皮肤更新,减轻创面炎症反应、促进肉芽组织形成、纤维细胞的快速增殖、从而加速组织创面愈合的过程,具备保湿、舒缓和祛痘等多重功效。
上述祛痘组合物的制备方法,包括以下步骤:
(1)将尿囊素、保湿剂加入至水中,加热至65-75℃,直至保湿剂搅拌溶解;
(2)待温度冷却至60℃以下时,加入季铵盐-73并搅拌均匀;
(3)依次加入皮肤调理剂、赤松叶提取物、乳酸杆菌发酵产物、泛醇、甘草酸二钾、防腐剂、增溶剂、辅料,搅拌均匀后即可过滤出料。
实施例2
本实施例提供了一种祛痘组合物,按质量分数包括以下组分:保湿剂10%、赤松叶提取物0.015%、乳酸杆菌发酵产物0.0075%、皮肤调理剂4%、尿囊素0.2%、泛醇0.4%、甘草酸二钾0.12%、防腐剂0.8%、增溶剂0.6%、辅料0.7%,余量为填料,本实施例与实施例1的区别在于:本实施例未加入有季铵盐-73。
实施例3
本实施例提供了一种祛痘组合物,按质量分数包括以下组分:保湿剂10%、季铵盐-73 0.02%、皮肤调理剂4%、尿囊素0.2%、泛醇0.4%、甘草酸二钾0.12%、防腐剂0.8%、增溶剂0.6%、辅料0.7%,余量为填料,本实施例与实施例1的区别在于:本实施例未加入有赤松叶提取物、乳酸杆菌发酵产物。
实施例4
本实施例提供了一种祛痘组合物,按质量分数包括以下组分:保湿剂10%、季铵盐-73 0.02%、赤松叶提取物0.015%、乳酸杆菌发酵产物0.0075%、皮肤调理剂4%、泛醇0.4%、甘草酸二钾0.12%、防腐剂0.8%、增溶剂0.6%、辅料0.7%,余量为填料,本实施例与实施例1的区别在于:本实施例未加入有尿囊素。
实施例5
本实施例提供了一种祛痘组合物,按质量分数包括以下组分:保湿剂10%、季铵盐-73 0.02%、赤松叶提取物0.015%、乳酸杆菌发酵产物0.0075%、皮肤调理剂4%、尿囊素0.2%、甘草酸二钾0.12%、防腐剂0.8%、增溶剂0.6%、辅料0.7%,余量为填料,本实施例与实施例1的区别在于:本实施例未加入有泛醇。
实施例6
本实施例提供了一种祛痘组合物,按质量分数包括以下组分:保湿剂10%、季铵盐-73 0.02%、赤松叶提取物0.015%、乳酸杆菌发酵产物0.0075%、皮肤调理剂4%、尿囊素0.2%、泛醇0.4%、防腐剂0.8%、增溶剂0.6%、辅料0.7%,余量为填料,本实施例与实施例1的区别在于:本实施例未加入有甘草酸二钾。
实施例7
本实施例提供了一种祛痘组合物,按质量分数包括以下组分:保湿剂10%、季铵盐-73 0.05%、赤松叶提取物0.02%、乳酸杆菌发酵产物0.01%、皮肤调理剂4%、尿囊素0.2%、泛醇0.4%、甘草酸二钾0.12%、防腐剂0.8%、增溶剂0.6%、辅料0.7%,余量为填料,本实施例与实施例1的区别在于:本实施例中季铵盐-73的质量分数为0.05%,赤松叶提取物的质量分数为0.02%、乳酸杆菌发酵产物的质量分数为0.01%。
实施例8
本实施例提供了一种祛痘组合物,按质量分数包括以下组分:保湿剂10%、季铵盐-73 0.002%、赤松叶提取物0.01%、乳酸杆菌发酵产物0.0045%、皮肤调理剂4%、尿囊素0.2%、泛醇0.4%、甘草酸二钾0.12%、防腐剂0.8%、增溶剂0.6%、辅料0.7%,余量为填料,本实施例与实施例1的区别在于:本实施例中季铵盐-73的质量分数为0.002%,赤松叶提取物的质量分数为0.01%、乳酸杆菌发酵产物的质量分数为0.0045%。
实施例9
本实施例提供了一种祛痘组合物,按质量分数包括以下组分:保湿剂10%、季铵盐-73 0.02%、赤松叶提取物0.015%、乳酸杆菌发酵产物0.0075%、皮肤调理剂4%、尿囊素0.15%、泛醇0.2%、甘草酸二钾0.05%、防腐剂0.8%、增溶剂0.6%、辅料0.7%,余量为填料,本实施例与实施例1的区别在于:本实施例中尿囊素的质量分数为0.15%,泛醇的质量分数为0.2%,甘草酸二钾的质量分数为0.05%。
实施例10
本实施例提供了一种祛痘组合物,按质量分数包括以下组分:保湿剂10%、季铵盐-73 0.02%、赤松叶提取物0.015%、乳酸杆菌发酵产物0.0075%、皮肤调理剂4%、尿囊素0.3%、泛醇1%、甘草酸二钾0.2%、防腐剂0.8%、增溶剂0.6%、辅料0.7%,余量为填料,本实施例与实施例1的区别在于:本实施例中尿囊素的质量分数为0.3%,泛醇的质量分数为1%,甘草酸二钾的质量分数为0.2%。
对照例1
本对照例与实施例1基本一致,不同之处在于:本对照例中未添加有季铵盐-73、赤松叶提取物和乳酸杆菌发酵产物的提取物、尿囊素、泛醇、甘草酸二钾。
对照例2
本对照例与实施例1基本一致,不同之处在于:本对照例中未添加有季铵盐-73、赤松叶提取物、乳酸杆菌发酵产物。
对照例3
本对照例与实施例1基本一致,不同之处在于:本对照例中未添加有尿囊素、泛醇、甘草酸二钾。
将以上实施例和对照例所得的祛痘组合物,制备成为祛痘原液,并选取对应的培养基去培养痤疮丙酸杆菌ATCC11827,其中选用的培养基为BHIA培养基,选用的试验仪器为厌氧培养箱(编号为QFM-A -P036)、生物安全柜(编号为QFM-B-P005)、低温恒温槽(编号为QFM-B-P014),且需要说明的是,每次选取祛痘原液作用时间为3min,且上述每个对照例与实施例均对应设置三组实验样本,三组试样样本均存在对应的对照组,通过抑菌率计算公式:(空白组菌落总数-实验样本菌落总数)/(实验样本菌落总数)×100%,计算对应的抑菌率,之后通过求取三组实验样本的平均抑菌率作为最终的抑菌率结果,上述各实施例与对照例的抑菌率结果如下表1所示:
表1
同时,将以上实施例和对照例所得的祛痘组合物,制备成为祛痘原液,并对其进行透明质酸酶抑制试验,试验所需溶液为乙酸缓冲液、透明质酸酶溶液、透明质酸钠溶液、十六烷基三甲基溴化铵(CTAB)溶液,试验所需仪器为:分析天平(型号为HX50002)、电热恒温培养箱(型号为HSX-250)、酶标仪(型号为是SpectralMAX i3),首先,对于每个祛痘原液按一定比例,将其稀释为三个不同浓度的样本溶液,且三个浓度依次递增,将三个样本溶液按浓度高至低依次记为第一溶液、第二溶液与第三溶液,第一溶液、第二溶液与第三溶液浓度分别为0.063g/ml、0.125g/ml、0.25g/ml;
对于每个样本溶液,将其分为两组,即A与B,往A溶液中加入0.1ml的透明质酸酶溶液,37℃孵育10min,之后加入0.1ml的0.04%透明质酸钠溶液,37℃酶解45min,之后加入0.2mlCTAB溶液,37℃沉淀5min,吸取200uL的反应后的溶液于96孔板中,测定400nm处的吸光值,以得到A结果;往B溶液中加入0.1ml的乙酸缓冲液,37℃孵育10min,之后加入0.1ml的0.04%透明质酸钠溶液,37℃酶解45min,之后加入0.2mlCTAB溶液,37℃沉淀5min,吸取200uL的反应后的溶液于96孔板中,测定400nm处的吸光值,以得到B结果;称取0.1ml的三级水,往三级水中加入0.1ml的透明质酸酶溶液,37℃孵育10min,之后加入0.1ml的0.04%透明质酸钠溶液,37℃酶解45min,之后加入0.2mlCTAB溶液,37℃沉淀5min,吸取200uL的反应后的溶液于96孔板中,测定400nm处的吸光值,以得到C结果;称取0.1ml的三级水,往三级水中加入0.1ml的乙酸缓冲液,37℃孵育10min,之后加入0.1ml的0.04%透明质酸钠溶液,37℃酶解45min,之后加入0.2mlCTAB溶液,37℃沉淀5min,吸取200uL的反应后的溶液于96孔板中,测定400nm处的吸光值,以得到D结果;
具体的透明质酸酶抑制率计算结果为{(D结果-C结果)-(B结果-A结果)}/(D结果-C结果)×100%,对于每个实施例与对照例中的第一溶液、第二溶液与第三溶液均进行上述操作并计算其透明质酸酶抑制率,并选取第三溶液的透明质酸酶抑制率作为最终的透明质酸酶抑制率试验结果,且根据第一溶液、第二溶液与第三溶液的透明质酸酶抑制率之间是否呈递增关系判断样本是否具备舒缓效果,具体请参阅表2:
表2
请参阅表1,对比实施例2、3,当缺少季铵盐-73、赤松叶提取物和乳酸杆菌发酵产物时,此时抑菌率对比实施例1有明显下降,对比实施例4、5、6,当缺少尿囊素、甘草酸二钾与泛醇时,其抑菌率对比实施例1也有所下降,但其下降幅度没有实施例2、3高,对比实施例7、8,当祛痘组合物中的季铵盐-73、赤松叶提取物、乳酸杆菌发酵产物的含量过高或者过低时,也会对影响其抑菌率,但对比实施例2、3、4、5、6,其抑菌效果也较为优秀,而对于对照组1而言,其未添加季铵盐-73、赤松叶提取物、乳酸杆菌发酵产物、尿囊素、甘草酸二钾与泛醇,因此其抑菌率最低为7%,对比实施例1与对照例3可以看出,在祛痘组合物中添加尿囊素、甘草酸二钾与泛醇,配合季铵盐-73、赤松叶提取物、乳酸杆菌发酵产物能够进一步提升样本的祛痘性能;
同时参阅表1、实施例1~8、对照例1、2,可以看出,利用季铵盐-73、赤松叶提取物和乳酸杆菌发酵产物等为主要祛痘组合物,尿囊素、甘草酸二钾与泛醇可辅助提升季铵盐-73、赤松叶提取物和乳酸杆菌发酵产物的祛痘性能,通过季铵盐-73可以有效抑制痤疮丙酸杆菌的活性,维护微生态平衡,赤松叶提取物和乳酸杆菌发酵产物能抑制Toll样受体激活,减少炎症因子;
请参阅表2,当第一溶液、第二溶液与第三溶液的透明质酸酶抑制率之间满足递增关系,则可以认为样本具备舒缓效果,从实施例1与对照例1、2、3中可以看出尿囊素、甘草酸二钾与泛醇为主要舒缓成本,当样本中具备尿囊素、甘草酸二钾与泛醇且尿囊素占比为0.2%、泛醇占比为0.4%、甘草酸二钾占比为0.12%时,样本具备最优的舒缓效果,当样本中不具备尿囊素、甘草酸二钾与泛醇时,此时样本的舒缓效果不好且趋近于无,从实施例2、3、7、8可以看出,季铵盐-73、赤松叶提取物和乳酸杆菌发酵产物对舒缓效果影响较低,从实施例4、5、6可以看出,尿囊素、甘草酸二钾与泛醇中缺少任意一样,则会对舒缓效果有较大影响,同时从实施例9、10可以看出,当祛痘组合物中的尿囊素、甘草酸二钾与泛醇的含量过高或者过低时,也会对影响其舒缓性能,同时对比实施例1与对照例2,可以得知在祛痘组合物中添加季铵盐-73、赤松叶提取物和乳酸杆菌发酵产物,配合尿囊素、甘草酸二钾与泛醇能够进一步提升样本的舒缓性能,通过配合尿囊素、甘草酸二钾与泛醇能促进细胞组织的生长,能影响表皮的快速粒状化过程,加快皮肤更新,减轻创面炎症反应、促进肉芽组织形成、纤维细胞的快速增殖、从而加速组织创面愈合的过程,具备保湿、舒缓和祛痘等多重功效。
值得说明的是,在本发明的再一实施例中,提供了一种祛痘精华水,祛痘精华水可由上述实施例中的祛痘组合物制备得到,按质量分数包括以下组分:
保湿剂(甘油4%、1、3-丙二醇5%、丁二醇4%)、季铵盐-73 0.02%、赤松叶提取物0.015%、乳酸杆菌发酵产物0.0075%、皮肤调理剂(扁桃酸0.2% 、精氨酸0.26%、糖脂0.12%、甘油辛酸酯0.000095%、黄檗树皮提取物0.00005%,欧百里香提取物0.00003%)、尿囊素0.2%、泛醇0.4%、甘草酸二钾0.12%、防腐剂(苯氧乙醇0.54%、苯甲酸钠0.01%、乙基己基甘油0.06%)、增溶剂(PEG-40 氢化蓖麻油 0.4%)、辅料(EDTA二钠0.03%、羟基乙酸0.00075%),余量为水。
其制备方法为:
(1)将甘油、1、3-丙二醇、尿囊素、丁二醇加入至水中,加热至65-75℃,直至搅拌溶解;
(2)待温度冷却至60℃以下时,加入苯氧乙醇、PEG-40 氢化蓖麻油并搅拌均匀;
(3)依次加入泛醇、甘草酸二钾、赤松叶提取物、乳酸杆菌发酵产物、季铵盐-73、糖脂、扁桃酸、精氨酸、甘油辛酸酯、黄檗树皮提取物、欧百里香提取物、苯甲酸钠、乙基己基甘油、EDTA二钠、羟基乙酸,搅拌均匀后即可过滤出料。
在本发明的再一实施例中,提供了一种祛痘啫喱,祛痘啫喱可由上述实施例中的祛痘组合物制备得到,按质量分数包括以下组分:
保湿剂(甘油4%、1、3-丙二醇5%、丁二醇4%)、季铵盐-73 0.02%、赤松叶提取物0.015%、乳酸杆菌发酵产物0.0075%、皮肤调理剂(烟酰胺3%、精氨酸0.5%、糖脂0.12%、甘油辛酸酯0.000095%、黄檗树皮提取物0.00005%,欧百里香提取物0.00003%)、尿囊素0.2%、泛醇0.4%、甘草酸二钾0.12%、防腐剂(苯氧乙醇0.54%、苯甲酸钠0.01%、乙基己基甘油0.06%)、增溶剂(PEG-40 氢化蓖麻油 0.4%)、辅料(EDTA 二钠0.03%、羟基乙酸0.00075%、增稠剂0.5%),余量为水。
其制备方法为:
(1)将增稠剂、甘油、1、3-丙二醇、尿囊素、EDTA二钠、丁二醇加入至水中,加热至65-75℃,直至搅拌溶解;
(2)待温度冷却至60℃以下时,加入苯氧乙醇、PEG-40 氢化蓖麻油、乙基己基甘油并搅拌均匀;
(3)依次加入赤松叶提取物、乳酸杆菌发酵产物、泛醇、甘草酸二钾、季铵盐-73、糖脂、精氨酸、甘油辛酸酯、黄檗树皮提取物、欧百里香提取物、苯甲酸钠、羟基乙酸,搅拌均匀后即可过滤出料。
在本发明的再一实施例中,提供了一种祛痘精华液,祛痘精华液可由上述实施例中的祛痘组合物制备得到,按质量分数包括以下组分:
保湿剂(甘油4%、1、3-丙二醇5%、丁二醇4%)、季铵盐-73 0.02%、赤松叶提取物0.015%、乳酸杆菌发酵产物0.0075%、皮肤调理剂(烟酰胺3%、精氨酸0.5%、糖脂0.12%、甘油辛酸酯0.000095%、黄檗树皮提取物0.00005%,欧百里香提取物0.00003%)、尿囊素0.2%、泛醇0.4%、甘草酸二钾0.12%、防腐剂(苯氧乙醇0.54%、苯甲酸钠0.01%、乙基己基甘油0.06%)、增溶剂(PEG-40 氢化蓖麻油 0.3%)、辅料(EDTA 二钠0.03%、羟基乙酸0.00075%、增稠剂0.1%),余量为水。
其制备方法为:
(1)将增稠剂、甘油、1、3-丙二醇、尿囊素、EDTA二钠、丁二醇加入至水中,加热至65-75℃,直至搅拌溶解;
(2)待温度冷却至60℃以下时,加入苯氧乙醇、PEG-40 氢化蓖麻油、乙基己基甘油并搅拌均匀;
(3)依次加入赤松叶提取物、乳酸杆菌发酵产物、泛醇、甘草酸二钾、季铵盐-73、糖脂、精氨酸、甘油辛酸酯、黄檗树皮提取物、欧百里香提取物、苯甲酸钠、羟基乙酸,搅拌均匀后即可过滤出料。
在本说明书的描述中,参考术语“一个实施例”、“一些实施例”、 “示例”、“具体示例”、或“一些示例”等的描述意指结合该实施例或示例描述的具体特征、结构、材料或者特点包含于本发明的至少一个实施例或示例中。在本说明书中,对上述术语的示意性表述不一定指的是相同的实施例或示例。而且,描述的具体特征、结构、材料或者特点可以在任何的一个或多个实施例或示例中以合适的方式结合。
以上所述实施例仅表达了本发明的几种实施方式,其描述较为具体和详细,但并不能因此而理解为对本发明专利范围的限制。应当指出的是,对于本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。因此,本发明专利的保护范围应以所附权利要求为准。
Claims (9)
1.一种祛痘组合物,其特征在于,按质量分数包括以下组分:保湿剂7-20%、季铵盐-730.002-0.05%、赤松叶提取物0.01-0.02%、乳酸杆菌发酵产物0.0045-0.01%、皮肤调理剂0.2-5%、尿囊素0.15-0.3%、泛醇0.2-1%、甘草酸二钾0.05-0.2%、防腐剂0.6-1%、增溶剂0.3-0.8%、辅料0.1-3%,以上组分的质量分数相加不超过100%,余量为填料;
其中,所述皮肤调理剂为扁桃酸、精氨酸、糖脂、甘油辛酸酯、黄檗树皮提取物、欧百里香提取物;
其中,赤松叶提取物、乳酸杆菌发酵产物可通过以下方法制备得到:提取赤松叶水,将赤松叶水与沙克乳酸杆菌混合并在37℃的条件下发酵48h,之后经过灭菌、过滤、浓缩、添加丁二醇、羟丙基环糊精和双丙甘醇、过滤得到最终产物即为赤松叶提取物、乳酸杆菌发酵产物。
2.根据权利要求1所述的祛痘组合物,其特征在于,所述保湿剂为甘油、1、3-丙二醇、丁二醇中的任意一种或多种的组合。
3.根据权利要求1所述的祛痘组合物,其特征在于,所述防腐剂为苯氧乙醇、苯甲酸钠、乙基己基甘油中的一种或多种的组合。
4.根据权利要求1所述的祛痘组合物,其特征在于,所述增溶剂为PEG-40 氢化蓖麻油。
5.根据权利要求1所述的祛痘组合物,其特征在于,所述辅料为EDTA二钠、羟基乙酸、增稠剂中的任一种或多种的组合。
6.根据权利要求5所述的祛痘组合物,其特征在于,所述增稠剂为卡波姆、丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物、黄原胶中的任一种或多种的组合。
7.根据权利要求1所述的祛痘组合物,其特征在于,所述填料为水。
8.根据权利要求1~7任意一项所述的祛痘组合物的制备方法,其特征在于,包括以下步骤:
(1)将尿囊素、保湿剂加入至填料中,加热至第一预设温度,直至保湿剂搅拌溶解;
(2)待温度冷却至第二预设温度以下时,加入季铵盐-73并搅拌均匀;
(3)依次加入皮肤调理剂、赤松叶提取物、乳酸杆菌发酵产物、泛醇、甘草酸二钾、防腐剂、增溶剂、辅料,搅拌均匀后即可过滤出料。
9.根据权利要求8所述的祛痘组合物的制备方法,其特征在于,第一预设温度为65-75℃,第二预设温度为60℃。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311765339.6A CN117427027B (zh) | 2023-12-21 | 2023-12-21 | 一种祛痘组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311765339.6A CN117427027B (zh) | 2023-12-21 | 2023-12-21 | 一种祛痘组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117427027A CN117427027A (zh) | 2024-01-23 |
CN117427027B true CN117427027B (zh) | 2024-04-23 |
Family
ID=89558677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311765339.6A Active CN117427027B (zh) | 2023-12-21 | 2023-12-21 | 一种祛痘组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117427027B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117959235A (zh) * | 2024-01-31 | 2024-05-03 | 广州市兰轩生物科技有限公司 | 一种调节皮肤微生态平衡的组合物及其应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017036239A1 (zh) * | 2015-08-28 | 2017-03-09 | 无限极(中国)有限公司 | 一种祛痘护肤品及其制备方法 |
CN107789308A (zh) * | 2017-11-06 | 2018-03-13 | 诺斯贝尔化妆品股份有限公司 | 一种温和控油祛痘精华 |
CN109152702A (zh) * | 2016-04-12 | 2019-01-04 | 伊拉斯吹斯制药有限公司 | 用于化合物的局部应用的组合物 |
CN111568834A (zh) * | 2020-06-29 | 2020-08-25 | 广州广妆生物科技有限公司 | 一种纯天然植物祛痘淡印组合物、包含其的精华液及制备方法和应用 |
CN114515251A (zh) * | 2022-02-14 | 2022-05-20 | 广州盛妍精细化工有限公司 | 一种祛痘修复的组合物及制备方法 |
CN116869845A (zh) * | 2023-08-01 | 2023-10-13 | 广州优蓓生物科技有限公司 | 一种舒缓修护组合物、舒缓修护冻干式面膜及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3694489A4 (en) * | 2017-10-11 | 2021-06-30 | Illustris Pharmaceuticals, Inc. | METHODS AND COMPOSITIONS FOR TOPICAL ADMINISTRATION |
-
2023
- 2023-12-21 CN CN202311765339.6A patent/CN117427027B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017036239A1 (zh) * | 2015-08-28 | 2017-03-09 | 无限极(中国)有限公司 | 一种祛痘护肤品及其制备方法 |
CN109152702A (zh) * | 2016-04-12 | 2019-01-04 | 伊拉斯吹斯制药有限公司 | 用于化合物的局部应用的组合物 |
CN107789308A (zh) * | 2017-11-06 | 2018-03-13 | 诺斯贝尔化妆品股份有限公司 | 一种温和控油祛痘精华 |
CN111568834A (zh) * | 2020-06-29 | 2020-08-25 | 广州广妆生物科技有限公司 | 一种纯天然植物祛痘淡印组合物、包含其的精华液及制备方法和应用 |
CN114515251A (zh) * | 2022-02-14 | 2022-05-20 | 广州盛妍精细化工有限公司 | 一种祛痘修复的组合物及制备方法 |
CN116869845A (zh) * | 2023-08-01 | 2023-10-13 | 广州优蓓生物科技有限公司 | 一种舒缓修护组合物、舒缓修护冻干式面膜及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN117427027A (zh) | 2024-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN117427027B (zh) | 一种祛痘组合物及其制备方法 | |
CN112006954B (zh) | 一种洗发乳及其制备方法 | |
CN114306432B (zh) | 一种具有防脱生发功能的植物外泌体组合物及其制备方法 | |
CN116003577B (zh) | 一种用于皮肤舒缓修复的重组胶原蛋白及其应用 | |
CN113018246B (zh) | 一种具有缓解头皮炎症的益生菌洗发水及其制备方法 | |
CN113368300A (zh) | 一种eps与贻贝提取物复配修复皮肤屏障敷料及其制备方法 | |
CN115317417A (zh) | 一种含愈创木提取物的修护痘敏肌的组合物及其护肤品 | |
CN111529478A (zh) | 一种保湿滋润型免洗手消毒剂及其制备方法 | |
CN113908097B (zh) | 一种祛痘组合物及其应用 | |
CN110721117A (zh) | 一种美容护肤化妆品冻干粉制剂及其在溶液剂上的应用 | |
DE69520693T2 (de) | Hydroxyprolin reiche proteine und sie enthaltende pharmazeutische und kosmetische zubereitungen | |
CN110897911A (zh) | 一种新的抗痘组合物及其在化妆品中的应用 | |
CN107375152A (zh) | 一种阳离子杀菌凝胶及其制备方法、和包含该阳离子杀菌凝胶的芦荟抑菌凝胶制品 | |
CN107028830B (zh) | 一种防止疤痕增生的药品及其制备工艺 | |
CN109875944A (zh) | 一种面膜液及其制备方法 | |
CN113456514A (zh) | 一种含玻尿酸的头皮养护组合物及其制备方法和应用 | |
CN115569079B (zh) | 一种保湿控油精华液及其制备方法和应用 | |
CN116473871A (zh) | 一种含有β-葡聚糖的皮肤修复敷料及其制备方法 | |
CN114053175B (zh) | 一种祛痘产品及其制备方法 | |
CN113350255B (zh) | 一种低刺激抑菌化妆品及其制备方法 | |
CN111514053B (zh) | 一种具有祛痘功效的组合物及其制备方法和应用 | |
CN114848721A (zh) | 一种含植物提取物的祛痘组合物及其制备应用 | |
CN111870590B (zh) | 液体祛痘贴及其制备方法 | |
CN114469812A (zh) | 一种发酵型姜黄凝胶和薰衣草花水复配精华液及其制备方法 | |
CN114081939A (zh) | 一种抗菌肽Cbf-14水凝胶及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |